318 related articles for article (PubMed ID: 16442670)
1. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Julien C; Berthiaume L; Hadj-Tahar A; Rajput AH; Bédard PJ; Di Paolo T; Julien P; Calon F
Neurochem Int; 2006 Apr; 48(5):404-14. PubMed ID: 16442670
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
Ouattara B; Grégoire L; Morissette M; Gasparini F; Vranesic I; Bilbe G; Johns DR; Rajput A; Hornykiewicz O; Rajput AH; Gomez-Mancilla B; Di Paolo T
Neurobiol Aging; 2011 Jul; 32(7):1286-95. PubMed ID: 20036444
[TBL] [Abstract][Full Text] [Related]
3. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
[TBL] [Abstract][Full Text] [Related]
4. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
[TBL] [Abstract][Full Text] [Related]
5. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
Samadi P; Rajput A; Calon F; Grégoire L; Hornykiewicz O; Rajput AH; Di Paolo T
J Neuropathol Exp Neurol; 2009 Apr; 68(4):374-82. PubMed ID: 19287314
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
[TBL] [Abstract][Full Text] [Related]
8. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
9. Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration.
Stephenson DT; Li Q; Simmons C; Connell MA; Meglasson MD; Merchant K; Emborg ME
Neurobiol Dis; 2005 Nov; 20(2):347-59. PubMed ID: 15882945
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
Riahi G; Morissette M; Lévesque D; Rouillard C; Samadi P; Parent M; Di Paolo T
Neurochem Int; 2012 Dec; 61(7):1160-71. PubMed ID: 22940695
[TBL] [Abstract][Full Text] [Related]
11. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Guigoni C; Dovero S; Aubert I; Li Q; Bioulac BH; Bloch B; Gurevich EV; Gross CE; Bezard E
Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
[TBL] [Abstract][Full Text] [Related]
12. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
13. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
[TBL] [Abstract][Full Text] [Related]
14. Striatal histone modifications in models of levodopa-induced dyskinesia.
Nicholas AP; Lubin FD; Hallett PJ; Vattem P; Ravenscroft P; Bezard E; Zhou S; Fox SH; Brotchie JM; Sweatt JD; Standaert DG
J Neurochem; 2008 Jul; 106(1):486-94. PubMed ID: 18410512
[TBL] [Abstract][Full Text] [Related]
15. BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
Samadi P; Morissette M; Lévesque D; Di Paolo T
Mov Disord; 2010 Jan; 25(1):116-21. PubMed ID: 20014115
[TBL] [Abstract][Full Text] [Related]
16. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
Yasuda T; Fukuda-Tani M; Nihira T; Wada K; Hattori N; Mizuno Y; Mochizuki H
Exp Neurol; 2007 Aug; 206(2):308-17. PubMed ID: 17604022
[TBL] [Abstract][Full Text] [Related]
17. Genes regulated in MPTP-treated macaques and human Parkinson's disease suggest a common signature in prefrontal cortex.
Storvik M; Arguel MJ; Schmieder S; Delerue-Audegond A; Li Q; Qin C; Vital A; Bioulac B; Gross CE; Wong G; Nahon JL; Bezard E
Neurobiol Dis; 2010 Jun; 38(3):386-94. PubMed ID: 20206263
[TBL] [Abstract][Full Text] [Related]
18. Three-year tracking of fatty acid composition of plasma phospholipids in healthy children.
Guerra A; Demmelmair H; Toschke AM; Koletzko B
Ann Nutr Metab; 2007; 51(5):433-8. PubMed ID: 18025816
[TBL] [Abstract][Full Text] [Related]
19. Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.
Rajput AH; Fenton ME; Di Paolo T; Sitte H; Pifl C; Hornykiewicz O
Parkinsonism Relat Disord; 2004 Jun; 10(4):221-6. PubMed ID: 15120096
[TBL] [Abstract][Full Text] [Related]
20. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.
Miklossy J; Doudet DD; Schwab C; Yu S; McGeer EG; McGeer PL
Exp Neurol; 2006 Feb; 197(2):275-83. PubMed ID: 16336966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
